Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) announced participation in multiple investor conferences in February and March 2026. The company will host 1x1 meetings at BTIG on Feb 10, and deliver fireside chats at TD Cowen (Mar 4, 9:50 AM ET), Leerink (Mar 10, 1:00 PM ET) and Barclays (Mar 11, 1:00 PM ET).
Live and archived webcasts will be available in the Investors section at www.guardanthealth.com.
Guardant Health (Nasdaq: GH) announced publication in the Journal of Clinical Oncology of the largest study to date evaluating ctDNA for molecular residual disease (MRD) in resected stage III colon cancer.
In a phase III cohort of >2,000 patients, Guardant Reveal detected ctDNA in ~20% post-surgery and identified a four‑to‑six‑fold higher risk of recurrence or reduced survival versus standard staging; tumor fraction further stratified highest‑risk patients.
Guardant Health (Nasdaq: GH) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 19, 2026. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio and archived replay will be available on the company’s Investors website.
Guardant Health (NASDAQ: GH) announced FDA approval of Guardant360 CDx as a companion diagnostic to identify BRAF V600E-mutant metastatic colorectal cancer (mCRC) patients eligible for BRAFTOVI (encorafenib) plus cetuximab and chemotherapy, supported by Pfizer’s Phase 3 BREAKWATER trial.
The approval expands Guardant360 CDx’s role across solid tumors as the platform’s 25th companion diagnostic indication, enables non-invasive ctDNA testing for rapid treatment selection and resistance monitoring, and complements existing Medicare and commercial coverage representing >300 million covered lives.
Guardant Health (Nasdaq: GH) announced a multi-year global collaboration with Merck (MSD outside US/Canada) to use the Guardant Infinity Smart platform across Merck’s oncology programs.
The agreement names Guardant’s liquid and tissue biopsy tests as clinical-trial enrolling assays, contemplates development of novel therapies using Guardant liquid biopsy tests as companion diagnostics, and includes partnering for global commercialization in the US, Asia-Pacific, UK, and EU.
Guardant Health (Nasdaq: GH) reported preliminary, unaudited results for Q4 and full-year 2025, with Q4 revenue of ~$280M (+39% YoY) and FY2025 revenue of ~$981M (+33% YoY). Test volumes rose sharply: ~79,000 oncology tests in Q4 (+38% YoY) and ~276,000 oncology tests for FY2025 (+34% YoY). Shield screening volumes reached ~38,000 in Q4 and ~87,000 for FY2025, with nearly 100,000 patients screened since FDA approval. Preliminary free cash flow was negative ~$54M in Q4 and negative ~$233M for FY2025. Cash and marketable securities totaled ~$1.3B at year-end. Results are unaudited and subject to change; audited results expected on the February 2026 earnings call.
Guardant Health (Nasdaq: GH) announced on January 8, 2026 that its Shield blood test for colorectal cancer screening is now covered by TRICARE for active-duty service members and eligible family members with no copay for average-risk individuals ages 45 and older. Shield is the first and only blood test approved by the FDA as a primary screening option for colorectal cancer and is already covered by Medicare and the Veterans Affairs Community Care Network. The Department of Defense reports about 1.3 million active-duty service members who, along with their screening-eligible family members, gain access to a blood-based alternative to traditional screening. Colorectal cancer has a 91% five-year survival rate when detected early.
Guardant Health (Nasdaq: GH) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management is scheduled to present and take part in a Q&A on Monday, January 12, 2026 at 3:45 p.m. PT / 6:45 p.m. ET. Live and archived webcasts will be available in the company Investors section at www.guardanthealth.com.
Guardant Health (Nasdaq: GH) announced a strategic collaboration with Trial Library on December 11, 2025 to expand access to oncology clinical trials across the U.S. The partnership pairs Guardant’s real-world genomic dataset of more than 1 million patients tested with Trial Library’s AI matching and navigation platform active in 320+ clinics and with 1,500 providers. The collaboration aims to streamline identification, referral, remote eligibility verification and longitudinal navigation to boost enrollment among representative and underserved populations.
Key figures cited include >70% of patients open to trials versus 7% enrolled
Guardant Health (Nasdaq: GH) announced on December 9, 2025 the launch of FPG 360, an in-house liquid biopsy testing service at Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy. The facility will offer on-site testing based on Guardant360 CDx technology to support routine care and clinical research.
The collaboration is described as one of the first dedicated hospital-based liquid biopsy facilities in Italy and follows Guardant Health partnerships with Val d’Hebron/VHIO and The Royal Marsden. The release notes Italy records approximately 400,000 new malignant tumor cases annually and also references Guardant360 CDx certification under EU IVDR obtained last year.